See more : Hovnanian Enterprises, Inc. PFD DEP1/1000A (HOVNP) Income Statement Analysis – Financial Results
Complete financial analysis of Scinai Immunotherapeutics Ltd. (SCNI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scinai Immunotherapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mintra Holding AS (MNTR.OL) Income Statement Analysis – Financial Results
- Splendid Metal Products Limited (SMPL.NS) Income Statement Analysis – Financial Results
- The Landis Taipei Hotel Co., Ltd (5703.TWO) Income Statement Analysis – Financial Results
- Solar Alliance Energy Inc. (SAENF) Income Statement Analysis – Financial Results
- Asahi India Glass Limited (ASAHIINDIA.BO) Income Statement Analysis – Financial Results
Scinai Immunotherapeutics Ltd. (SCNI)
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.98K | 76.22K | 66.96K | 73.42K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -167.98K | -76.22K | -66.96K | -73.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 5.77M | 3.25M | 16.01M | 19.88M | 19.27M | 5.58M | 2.44M | 2.76M | 1.65M | 1.94M | 1.61M | 1.53M | 1.80M | 805.34K | 882.39K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.51M | 5.30M | 7.63M | 5.19M | 2.81M | 1.38M | 1.40M | 1.07M | 871.81K | 680.13K | 631.56K | 574.69K | 602.75K | 668.83K | 299.68K | 343.07K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -23.49M | 1.00 | -38.24K | -185.65K | -416.06K | -726.29K | -243.56K | -366.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.19M | 2.13M | 2.47M | 1.11M | 1.23M |
| Cost & Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.38M | 2.30M | 2.54M | 1.17M | 1.30M |
| Interest Income | 122.68K | 8.10M | 928.76 | -9.71K | 8.30K | 1.35M | 5.04K | 14.38K | 2.83K | 21.19K | 37.80K | 65.04K | 129.34K | 85.62K | 8.66K | 89.89K |
| Interest Expense | -317.00 | 5.05M | -3.15M | 338.76K | 4.28M | 3.78M | -129.95 | 100.00 | 7.80 | 1.69K | -1.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 514.00K | 562.00K | 471.00K | 468.56K | 461.69K | 69.53K | 123.55K | 162.32K | 161.62K | 173.75K | 204.46K | 190.18K | 167.98K | 76.22K | 66.96K | 73.42K |
| EBITDA | -9.19M | -10.50M | -10.39M | 2.75M | -22.21M | -20.54M | -6.67M | -2.93M | -2.74M | -1.92M | -2.00M | -2.24M | -1.99M | -2.41M | -1.10M | -1.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.72M | -11.06M | -10.87M | 2.28M | -22.69M | -20.61M | -6.80M | -3.09M | -2.90M | -2.09M | -2.20M | -2.38M | -2.30M | -2.54M | -1.17M | -1.30M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.22M | 5.27M | 2.67M | -3.67M | -8.93M | -2.85M | -3.13M | 704.94K | 283.33K | 97.02K | -113.91K | -51.25K | 142.22K | 53.68K | 6.87K | 88.21K |
| Income Before Tax | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.35 | -230.45 | -223.97 | -279.13 | -173.14 | -189.82 |
| EPS Diluted | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.33 | -230.45 | -223.97 | -279.13 | 0.00 | -189.82 |
| Weighted Avg Shares Out | 390.66K | 188.52K | 141.14K | 110.81K | 81.66K | 65.35K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 6.73K | 6.38K |
| Weighted Avg Shares Out (Dil) | 390.66K | 188.52K | 141.14K | 110.82K | 81.66K | 65.36K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 0.00 | 6.38K |
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
JERUSALEM , Aug. 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its...
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
JERUSALEM , Aug. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that...
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the Paul Erlich Institute (the PEI) for its drug development program towards Phase 1/2a clinical trial of its anti-IL-17A/F nanoAb (SCN-1) in Plaque Psoriasis Clarified preclinical toxicology and clinical program for Plaque Psoriasis...
Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
JERUSALEM , July 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced successful in-vivo...
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
JERUSALEM , July 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that...
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
JERUSALEM , July 3, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it...
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
JERUSALEM , July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today...
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is rocketing higher on Monday alongside heavy pre-market trading of the development-stage biopharmaceutical company's shares this morning. This has more than 7 million shares of SCNI stock changing hands as of this writing.
Source: https://incomestatements.info
Category: Stock Reports